Close
Digital Health & Ai Innovation summit 2026
APE 2026

Mirada Medical supplies deformable fusion technology study at ASTRO

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

FDA May Scrutinize Medical Device Cybersecurity...

The scrutiny by the US Food and Drug Administration...

US Lawmakers Push Access For AI-Powered...

The US bipartisan legislation, which was introduced in the...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Mirada Medical has integrated its multi-modal Deformable Fusion technology into Varian’s SmartAdapt application and will present a study assessing the efficacy of the technology for MR to CT deformable registration at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami, Florida.

Mirada will also be showcasing a new range of software planning tools in their exhibit (Booth #1257) that incorporate its fusion technologies to support: dose warping, dose summation, atlas based auto-contouring, deformable fusion of multi-sequence MR, PET and SPECT and single click contour warping to support adaptive re-planning.

Dr. Timor Kadir, Mirada Chief Science and Technology Officer says, We are proud that our industry leading registration technology has been incorporated into Varian’s SmartAdapt. The validation study demonstrates that diagnostic or treatment position MR can be reliably aligned to CT planning images. This technology brings the benefit of MRI’s unrivalled soft tissue differentiation into conventional CT based planning.

Dr. Mark Gooding, senior scientist at Mirada, will present the study and poster presentation  at ASTRO. The study was chosen from a record breaking 2,437 abstracts submitted for review to be presented. ASTRO is the largest gathering of radiation oncology specialists in the world. The study, titled “Assessing the quality of deformable CT-MR registration for the purpose of multi-modal radiotherapy planning,” examines the performance of Mirada’s multi-modal deformable registration algorithm for the fusion of head and neck, prostate and cervical diagnostic MR scans to CT planning volumes. Performance was assessed by experts in radiation oncology from four independent clinical institutions and quantitative errors were also measured using landmarks. In all cases, deformable registration significantly improved the alignment between MR and planning CT, approximately halving the registration error compared to conventional rigid alignment. The clinical experts’ assessment concluded that the results required minimal intervention prior to use in multi-modal contouring.

Latest stories

Related stories

FDA May Scrutinize Medical Device Cybersecurity More in 2026

The scrutiny by the US Food and Drug Administration...

US Lawmakers Push Access For AI-Powered Medical Devices

The US bipartisan legislation, which was introduced in the...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

Philips, Masimo Extend Partnership to Sensor Technologies

Philips and Masimo have gone on to renew their...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »